These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 11061544

  • 21. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 22. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation.
    Gründker C, Günthert AR, Millar RP, Emons G.
    J Clin Endocrinol Metab; 2002 Mar 01; 87(3):1427-30. PubMed ID: 11889221
    [Abstract] [Full Text] [Related]

  • 23. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
    Fister S, Günthert AR, Aicher B, Paulini KW, Emons G, Gründker C.
    Cancer Res; 2009 Aug 15; 69(16):6473-81. PubMed ID: 19638591
    [Abstract] [Full Text] [Related]

  • 24. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G, Sindermann H, Engel J, Schally AV, Gründker C.
    Neuroendocrinology; 2009 Aug 15; 90(1):15-8. PubMed ID: 19521066
    [Abstract] [Full Text] [Related]

  • 25. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A, Schulz H, Emons G, Gründker C.
    Gynecol Endocrinol; 2008 Jun 15; 24(6):331-8. PubMed ID: 18584413
    [Abstract] [Full Text] [Related]

  • 26. Cell growth inhibition and induction of apoptosis by snake venom toxin in ovarian cancer cell via inactivation of nuclear factor κB and signal transducer and activator of transcription 3.
    Song JK, Jo MR, Park MH, Song HS, An BJ, Song MJ, Han SB, Hong JT.
    Arch Pharm Res; 2012 May 15; 35(5):867-76. PubMed ID: 22644854
    [Abstract] [Full Text] [Related]

  • 27. Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation.
    Meyer C, Sims AH, Morgan K, Harrison B, Muir M, Bai J, Faratian D, Millar RP, Langdon SP.
    Endocr Relat Cancer; 2013 Feb 15; 20(1):123-36. PubMed ID: 23202794
    [Abstract] [Full Text] [Related]

  • 28. Modulation of TNF-alpha-induced apoptosis in corneal fibroblasts by transcription factor NF-kappaB.
    Mohan RR, Mohan RR, Kim WJ, Wilson SE.
    Invest Ophthalmol Vis Sci; 2000 May 15; 41(6):1327-36. PubMed ID: 10798647
    [Abstract] [Full Text] [Related]

  • 29. Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice.
    Lin QY, Wang YF, Weng HN, Sheng XJ, Jiang QP, Yang ZY.
    J Zhejiang Univ Sci B; 2012 Nov 15; 13(11):894-903. PubMed ID: 23125082
    [Abstract] [Full Text] [Related]

  • 30. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
    Arencibia JM, Schally AV, Halmos G, Nagy A, Kiaris H.
    Anticancer Drugs; 2001 Jan 15; 12(1):71-8. PubMed ID: 11272290
    [Abstract] [Full Text] [Related]

  • 31. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
    Arencibia JM, Bajo AM, Schally AV, Krupa M, Chatzistamou I, Nagy A.
    Anticancer Drugs; 2002 Oct 15; 13(9):949-56. PubMed ID: 12394258
    [Abstract] [Full Text] [Related]

  • 32. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
    Gründker C, Völker P, Griesinger F, Ramaswamy A, Nagy A, Schally AV, Emons G.
    Am J Obstet Gynecol; 2002 Sep 15; 187(3):528-37. PubMed ID: 12237622
    [Abstract] [Full Text] [Related]

  • 33. Antitumor effect of GnRH agonist in epithelial ovarian cancer.
    Kim JH, Park DC, Kim JW, Choi YK, Lew YO, Kim DH, Jung JK, Lim YA, Namkoong SE.
    Gynecol Oncol; 1999 Aug 15; 74(2):170-80. PubMed ID: 10419728
    [Abstract] [Full Text] [Related]

  • 34. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
    Emons G, Ortmann O, Teichert HM, Fassl H, Löhrs U, Kullander S, Kauppila A, Ayalon D, Schally A, Oberheuser F.
    Cancer; 1996 Oct 01; 78(7):1452-60. PubMed ID: 8839551
    [Abstract] [Full Text] [Related]

  • 35. A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells.
    Imai A, Furui T, Tamaya T, Mills GB.
    J Clin Endocrinol Metab; 2000 Sep 01; 85(9):3370-5. PubMed ID: 10999836
    [Abstract] [Full Text] [Related]

  • 36. Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.
    Arencibia JM, Schally AV, Krupa M, Bajo AM, Nagy A, Szepeshazi K, Plonowski A.
    Int J Oncol; 2001 Sep 01; 19(3):571-7. PubMed ID: 11494038
    [Abstract] [Full Text] [Related]

  • 37. Neuregulin expression, function, and signaling in human ovarian cancer cells.
    Gilmour LM, Macleod KG, McCaig A, Sewell JM, Gullick WJ, Smyth JF, Langdon SP.
    Clin Cancer Res; 2002 Dec 01; 8(12):3933-42. PubMed ID: 12473609
    [Abstract] [Full Text] [Related]

  • 38. The Chinese herbs Scutellaria baicalensis and Fritillaria cirrhosa target NFκB to inhibit proliferation of ovarian and endometrial cancer cells.
    Kavandi L, Lee LR, Bokhari AA, Pirog JE, Jiang Y, Ahmad KA, Syed V.
    Mol Carcinog; 2015 May 01; 54(5):368-78. PubMed ID: 24249479
    [Abstract] [Full Text] [Related]

  • 39. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C, Duwe F, Hellriegel M, Schweyer S, Emons G, Gründker C.
    Oncol Rep; 2011 May 01; 25(5):1481-7. PubMed ID: 21331448
    [Abstract] [Full Text] [Related]

  • 40. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J, Emons G, Pinski J, Schally AV.
    Expert Opin Investig Drugs; 2012 Jun 01; 21(6):891-9. PubMed ID: 22577891
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.